Array melanoma drugs show significant survival vs Roche drug in study

(Reuters) - A combination of experimental drugs from Array BioPharma Inc kept patients with advanced melanoma associated with a common gene mutation alive for nearly three years and twice as long as a rival Roche Holding AG medicine, according to data from a late stage study released on Tuesday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news